Evaluation of the NYVAC C vaccine in HIV-negative individuals
A trial to look for a vaccine to prevent HIV
What was this study about?
Around the world, about 11,000 people are infected with the HIV virus every day, and AIDS is now the fourth commonest cause of death worldwide. Even though effective treatment is available, over 90% of HIV infections occur in developing countries, where governments find it hard to treat everyone who is infected with the virus. But even in populations where treatment is widely available, such as homosexual men in developed countries, the epidemic persists. So researchers want to develop a vaccine to protect people from the HIV virus.
This phase I trial aimed to test the use of a vaccine called NYVAC-C. It was developed by researchers in the UK and Switzerland.
What difference did this study make?
This phase I trial aimed to test the safety of the vaccine. There were no serious adverse events.
Researchers learned two important lessons from this trial:
- The first was about how long it takes to develop a vaccine from a laboratory to completing a clinical trial. EVO1 had a grant for three years, but it took much longer than to develop the vaccine and carry out this Phase I trial.
- The second was about the importance of ensuring that laboratory staff in different countries adopt a consistent approach.
Type of study
Who funded the study?
The trial was funded through the European Commission, as part of their Fifth Framework Programme. The vaccine NYVAC C was supplied by the drug company Aventis Pasteur.
When did it take place?
This trial recruited patients in 2003. The results of the trial were published in 2008.
Where did it take place?
St Mary’s Hospital, London, and Centre Hospitalier Universitaire Vaudois (CHUV) in Switzerland.
Who was included?
24 healthy people who were HIV negative.